Literature DB >> 31604529

The N-termini of GRK2 and GRK3 simulate the stimulating effects of RKIP on β-adrenoceptors.

Theopisti Maimari1, Cornelius Krasel2, Moritz Bünemann3, Kristina Lorenz4.   

Abstract

The Raf kinase inhibitor protein (RKIP) activates β-adrenoceptors (β-AR) and thereby induces a well-tolerated cardiac contractility and prevents heart failure in mice. Different to RKIP-mediated β-AR activation, chronic activation of β-AR by catecholamines was shown to be detrimental for the heart. RKIP is an endogenous inhibitor of G protein coupled receptor kinase 2 (GRK2); it binds GRK2 and thereby inhibits GRK2 mediated β-AR phosphorylation and desensitization. Here, we evaluate RKIP-mediated effects on β-AR to explore new strategies for β-AR modulation. Co-immunoprecipitation assays and pull-down assays revealed subtype specificity of RKIP for the cardiac GRK isoforms GRK2 and GRK3 - not GRK5 - as well as several RKIP binding sites within their N-termini (GRK21-185 and GRK31-185). Overexpression of these N-termini prevented β2-AR phosphorylation and internalization, subsequently increased receptor signaling in HEK293 cells and cardiomyocyte contractility. Co-immunoprecipitation assays of β2-AR with these N-terminal GRK fragments revealed a direct interaction suggesting a steric interference of the fragments with the functional GRK-receptor interaction. Altogether, N-termini of GRK2 and GRK3 efficiently simulate RKIP effects on β-AR signaling in HEK293 cells and in cardiomyocytes by their binding to β2-AR and, thus, provide important insights for the development of new strategies to modulate β2-AR signaling.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiomyocyte contractility; GPCR; GRK; Raf kinase inhibitor protein; β-adrenoceptors

Year:  2019        PMID: 31604529     DOI: 10.1016/j.bbrc.2019.09.135

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  The potential of remdesivir to affect function, metabolism and proliferation of cardiac and kidney cells in vitro.

Authors:  Katja Merches; Leonie Breunig; Julia Fender; Theresa Brand; Vanessa Bätz; Svenja Idel; Laxmikanth Kollipara; Yvonne Reinders; Albert Sickmann; Angela Mally; Kristina Lorenz
Journal:  Arch Toxicol       Date:  2022-05-17       Impact factor: 6.168

2.  Raf kinase inhibitory protein reduces bradykinin receptor desensitization.

Authors:  Samuel B Chivers; Allison Doyle Brackley; Nathaniel A Jeske
Journal:  J Neurochem       Date:  2022-05-08       Impact factor: 5.546

Review 3.  Harnessing RKIP to Combat Heart Disease and Cancer.

Authors:  Kristina Lorenz; Marsha Rich Rosner
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.